Together these results demonstrated that MTC-derived cells are sensitive to treatment with a pharmaceutical inhibitor of COX activity, and suggested that COX4 could represent a therapeutic target in MTCs. This evidence concerns the gene COX4I2 and medullary thyroid gland carcinoma.